Cerus (CERS) Chief Legal Officer receives 200,000-share RSU stock grant
Cerus Corp.'s Chief Legal Officer, Chrystal Jensen, was granted 200,000 Restricted Stock Units (RSUs) as a stock-based compensation award on April 1, 2026. These RSUs, valued at $0.00 per share for compensation purposes, will vest in full one year from the grant date, provided Jensen remains in continuous service. Following this grant, Jensen directly holds 1,146,131 shares of Cerus common stock, reinforcing her equity stake in the company.
Cerus (CERS) CFO receives 200,000-share RSU grant, lifts holdings to 1.24M
Cerus Corporation's Chief Financial Officer, Kevin Dennis Green, has received a grant of 200,000 Restricted Stock Units (RSUs) of common stock. This grant, valued at $0.00 per share as a compensation award, will vest fully one year from the grant date, subject to his continuous service to the company. Following this transaction, Green's direct holdings in Cerus common shares have increased to 1,240,551.
CERS SEC Filings - Cerus 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to SEC filings for Cerus Corporation (NASDAQ: CERS), including 10-K, 10-Q, and 8-K forms. It offers detailed financial information, business risks, and corporate governance updates, enhanced with AI-powered summaries and impact analysis for investors. Recent filings include an amended 13G/A from Baker Brothers disclosing Cerus shares and an 8-K detailing a leadership transition where the CEO assumed the chair role.
CERS Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Cerus Corp (CERS) from Intellectia.AI. It indicates a "Strong Buy" consensus based on various technical signals, including moving averages and oscillators. The analysis details key momentum indicators, support and resistance levels, and Cerus Corp's performance relative to its moving averages.
Cerus Corp (CERS) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Cerus Corp (CERS). It is hosted on Capital.com, an online trading platform.
Vanguard disaggregates holdings after realignment; Cerus Corp (NASDAQ: CERS)
Vanguard has filed an amended Schedule 13G/A, reporting a 0% beneficial ownership in Cerus Corp (NASDAQ: CERS) following an internal realignment that took effect on January 12, 2026. This realignment means that certain Vanguard subsidiaries will now report their holdings separately. The filing indicates that Vanguard itself no longer holds voting or dispositive power over Cerus Corp shares.
Soleus Capital (NASDAQ: CERS) discloses 5.1% position in Cerus
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.1% beneficial ownership stake in Cerus Corporation (NASDAQ: CERS), totaling 9,828,700 shares. This disclosure, filed as a SCHEDULE 13G, indicates shared voting and dispositive power over these shares among Soleus entities and Guy Levy. The ownership percentage is calculated based on 192,171,776 shares of Cerus common stock outstanding as of February 5, 2026.
Cerus (CERS) COO share sale covers taxes on RSU vesting
Cerus Corp's Chief Operating Officer, Vivek K. Jayaraman, sold 165,200 shares of common stock at a weighted average price of $1.6572 per share on March 12, 2026. This transaction was conducted under a Rule 10b5-1 instruction to cover tax withholding obligations and brokerage fees associated with the vesting of restricted stock units, and was not a discretionary sale. Following the sale, Jayaraman directly holds 1,747,674 shares of Cerus common stock.
Cerus Corp CEO Greenman sells $742k in shares
Cerus Corp CEO William Mariner Greenman sold 447,757 shares of common stock worth $742,022. The sale was primarily to cover tax obligations and brokerage fees related to restricted stock units, not a discretionary action. This transaction follows recent company news including strong Q4 2025 financial results and a planned leadership transition with Vivek Jayaraman succeeding Greenman as CEO in July 2026.
Cerus Appoints Vivek Jayaraman As Chief Executive Officer
Cerus Corp. has announced that Vivek Jayaraman, its current chief operating officer, will become president and chief executive officer, effective July 1, 2026. Current CEO William “Obi” Greenman will transition to executive chairman of the board. Jayaraman, who joined Cerus in 2016, has been instrumental in growing the company's annual product revenue from under $40 million to over $200 million.
Cerus Corp COO Jayaraman sells $273k in shares By Investing.com
Cerus Corp Chief Operating Officer Vivek K. Jayaraman sold 165,200 shares of common stock for $273,769, primarily to cover tax obligations. Despite the sale, he still directly owns 1,747,674 shares, and the company's stock shows volatility with a 43% 6-month return. Jayaraman is also set to become Cerus Corporation's new President and CEO effective July 1, 2026.
Jensen, Cerus Corp chief legal officer, sells $187k in stock
Jensen Chrystal, Chief Legal Officer of Cerus Corp (NASDAQ:CERS), sold 113,008 shares of company stock for a total of $187,276 on March 12, 2026. This transaction comes as the company recently reported strong Q4 2025 financial results, exceeding revenue projections, and announced a new President and CEO, Vivek Jayaraman, effective July 2026. Despite the insider sale and a recent stock dip, InvestingPro analysis suggests the stock is currently undervalued.
Cerus Corp COO Jayaraman sells $273k in shares
Cerus Corp's COO, Vivek K. Jayaraman, sold 165,200 shares of common stock for $273,769 on March 12, 2026, as part of a tax obligation plan. Despite a year-to-date decline, the stock has seen a 43% return over six months and is considered undervalued by InvestingPro. Jayaraman is also set to become the company's new President and CEO effective July 1, 2026.
Cerus (CERS) CEO sells 447,757 shares under 10b5-1 tax plan
Cerus Corp. President and CEO William Mariner Greenman sold 447,757 shares of common stock on March 12, 2026, at a weighted average price of $1.6572 per share. This sale was conducted under a Rule 10b5-1 plan to cover statutory tax withholding obligations and brokerage fees related to the vesting of restricted stock units, and was not a discretionary transaction. Following the sale, Greenman directly owns 4,998,493 shares of Cerus common stock.
Cerus (CERS) CFO share sale covers taxes on RSU vesting
Cerus Corporation's CFO, Kevin Dennis Green, reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. This sale was conducted under a Rule 10b5-1 instruction to cover statutory tax withholding obligations and brokerage fees related to the vesting of restricted stock units, and was not a discretionary sale. Following this transaction, Green directly holds 1,040,551 shares of Cerus common stock.
Cerus Corp (CERS) CMO sells 101,740 shares for RSU tax withholding
Cerus Corp's Chief Medical Officer, Benjamin Richard J, sold 101,740 shares of common stock at a weighted average price of $1.6572 per share. This transaction was not a discretionary sale but was executed under a Rule 10b5-1 plan to cover tax withholding obligations and brokerage fees related to the vesting of restricted stock units. Following this sale, Benjamin Richard J directly holds 777,361 shares in the company.
Cerus Corp: chief medical officer Benjamin sells $168k in shares By Investing.com
Cerus Corp's Chief Medical Officer, Richard J. Benjamin, sold 101,740 shares for $168,603 to cover tax obligations. Despite this sale, Benjamin still holds 777,361 shares, and the company's stock is considered undervalued by InvestingPro. Cerus also reported strong Q4 2025 revenues and announced a new CEO, Vivek Jayaraman, effective July 1, 2026.
Cerus Corp CFO green sells $211k in shares
Cerus Corp's CFO, Kevin Dennis Green, sold 127,544 shares for $211,365 to cover tax obligations and brokerage fees related to restricted stock vesting, not a discretionary sale. Following this, Green still directly owns over 1 million shares. InvestingPro analysis suggests the stock is currently undervalued, despite a recent 6.74% dip.
Insider Selling: Cerus (NASDAQ:CERS) Insider Sells 113,008 Shares of Stock
Cerus (NASDAQ:CERS) insider Chrystal Jensen sold 113,008 shares of stock for approximately $187,593 on March 12, reducing her stake by 10.67%. The company recently reported quarterly earnings that met analyst estimates for EPS and beat revenue expectations, but it remains unprofitable. Analyst sentiment for Cerus has recently turned negative, with an average rating of "Reduce."
Cerus Corp COO Jayaraman sells $273k in shares
Cerus Corp COO Vivek K. Jayaraman sold 165,200 shares amounting to $273,769 on March 12, 2026, to cover tax obligations. Despite a recent stock decline year-to-date, the company exceeded Q4 2025 revenue projections and announced Jayaraman's promotion to President and CEO effective July 1, 2026. Jayaraman will also join the board of directors.
Cerus Corp COO Jayaraman sells $273k in shares
Cerus Corp's COO, Vivek K. Jayaraman, sold 165,200 shares amounting to $273,769 due to tax obligations from vested restricted stock units. This transaction occurred amidst the company's strong Q4 2025 financial results and an announcement of Jayaraman's promotion to President and CEO, effective July 1, 2026. Jayaraman will retain 1,747,674 shares in the company.
Jensen, Cerus Corp chief legal officer, sells $187k in stock
Cerus Corp's Chief Legal Officer, Jensen Chrystal, sold 113,008 shares of company stock for over $187,000 on March 12, 2026. This transaction leaves Chrystal with 946,131 direct shares in the company. The sale follows a period where the stock saw a 43% gain over six months, despite a recent 6.7% drop.
Cerus Corp: chief medical officer Benjamin sells $168k in shares
Cerus Corp's Chief Medical Officer, Richard J. Benjamin, sold 101,740 shares of the company's common stock for approximately $168,603 to cover tax obligations. The company recently reported strong financial results for Q4 2025, with revenues exceeding projections and announced a leadership change with Vivek Jayaraman becoming the new President and CEO. Despite recent stock fluctuations, InvestingPro analysis suggests the stock is undervalued.
Cerus (CERS) CLO sells shares under 10b5-1 to cover taxes
Cerus Corp's Chief Legal Officer, Chrystal Jensen, sold 113,008 shares of common stock at a weighted average price of $1.6572 per share on March 12, 2025. This sale was conducted under a Rule 10b5-1 plan to cover tax withholding obligations and brokerage fees related to vesting restricted stock units and was not a discretionary sale. Following the transaction, Jensen still retains a substantial direct holding of 946,131 shares of Cerus common stock.
Cerus (CERS) promotes COO Vivek Jayaraman to CEO with $3M equity awards
Cerus Corporation has announced that its Chief Operating Officer, Vivek Jayaraman, will assume the role of President and Chief Executive Officer effective July 1, 2026. Current CEO William “Obi” Greenman will transition to Executive Chairman. Jayaraman's compensation package includes an annual base salary of $740,000, a target annual bonus of up to 80% of his base salary, alongside equity awards totaling $3,000,000 in target value.
COO who drove Cerus revenue past $200M will now run the company
Cerus Corporation has announced that Vivek Jayaraman, currently its Chief Operating Officer, will be promoted to President and Chief Executive Officer, effective July 1, 2026. Current CEO William “Obi” Greenman will transition to Executive Chairman of the Board. Jayaraman has been instrumental in growing Cerus's annual product revenue from under $40 million to over $200 million in 2025 during his tenure.
CERS Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for CERS stock, focusing on Cerus Corporation's Q4 2025 earnings and 2026 outlook. Key highlights include record product revenue exceeding $206 million in 2025, an estimated 600,000 patients receiving INTERCEPT-treated blood components, and a 2026 product revenue forecast of $224 million to $228 million. The company aims to continue expanding global access to INTERCEPT technologies and improving financial performance.
Cerus CFO Kevin Green sells $169k in shares
Cerus Corp CFO Kevin Green sold 83,021 shares of common stock for approximately $169,646 on March 5 and 6, 2026, amid a 12% stock price decline over the past week. Despite the sales, Green also acquired 63,854 shares on March 5 and still directly owns over a million shares in the company. InvestingPro analysis suggests the stock is currently undervalued, with the company recently reporting strong Q4 2025 revenues exceeding expectations.
Cerus (CERS) CMO sells 125,894 shares, receives 55,220-share grant
Cerus Corp's Chief Medical Officer, Benjamin Richard J, reported receiving a grant of 55,220 common shares on March 5, 2026. Following this, he sold a total of 125,894 common shares in open-market transactions between March 5, 6, and 9, 2026, at weighted average prices ranging from $1.88 to $2.06 per share. These sales were non-discretionary and made under a Rule 10b5-1 trading plan to cover tax withholding and related fees.
CERUS (CERS) CEO gets 193k-share grant, sells 78k shares to cover tax withholding
CERUS CORP President and CEO William Mariner Greenman reported acquiring 193,270 shares as a grant on March 5, 2026. He subsequently sold 78,187 shares on March 6, 2026, at a weighted average price of $2.0055 per share, to cover tax withholding and brokerage fees, not as a discretionary sale. Following these transactions, Greenman directly held 5,446,250 shares of CERUS common stock.
Cerus corp chief medical officer sells shares worth $250k
Richard J. Benjamin, Chief Medical Officer of Cerus Corp, sold approximately $250,931 worth of common stock between March 5 and March 9, 2026. These sales, primarily executed under a 10b5-1 trading plan and for tax obligations, occurred while the company's stock experienced volatility. Benjamin also acquired shares without monetary transaction, increasing his overall holdings, and the company recently reported strong financial results for Q4 2025.
Cerus Corp COO Jayaraman sells $68k in shares
Cerus Corp's COO, Vivek K. Jayaraman, sold 34,094 shares of common stock for $68,375. This sale was made to cover tax withholding obligations and brokerage fees related to restricted stock units, not as a discretionary sale. Jayaraman also acquired 80,320 shares at no cost and now directly owns 1,912,874 shares of Cerus Corp.
Cerus Corp chief medical officer sells shares worth $202k
Richard J. Benjamin, Chief Medical Officer of Cerus Corp, sold over $202,000 worth of company shares between March 5 and March 9, 2026, while also acquiring 55,220 shares at zero cost. These insider transactions occurred amidst a 9.4% decline in the stock over the past week, though shares are up 63.6% over the last six months. Cerus Corporation also recently reported strong financial performance with Q4 2025 revenues of $233.8 million, surpassing projections.
Richard Benjamin Sells 61,233 Shares of Cerus (NASDAQ:CERS) Stock
Cerus insider Richard Benjamin sold 61,233 shares of the company's stock on March 5th at an average price of $2.06, reducing his position by 6.09%. The biotechnology company recently reported Q4 EPS of ($0.01), meeting estimates, and revenue of $64.58 million, beating expectations. Despite exceeding revenue forecasts, Cerus remains unprofitable with a negative net margin and return on equity, and the stock currently holds a consensus "Hold" rating from analysts.
Cathie Wood's ARK Investment Acquires Shares in Cerus (CERS)
Cathie Wood's ARK Investment Management has purchased 612,000 shares of Cerus (CERS), a biotechnology company focused on blood transfusion safety through its INTERCEPT Blood System. While Cerus shows revenue growth, it faces financial challenges including negative profitability and a high debt-to-equity ratio, leading to a negative Altman Z-Score. Despite these risks and volatile stock performance, institutional investors show strong interest.
Cerus Corporation (NASDAQ:CERS) Q4 2025 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS) reported Q4 and full-year 2025 earnings, with total revenues reaching a record $233.8 million, up 16% from 2024. The company achieved strong growth in EMEA, continued positive traction with the INT200 illuminator launch, and increasing momentum in its U.S. IFC business, fueled by a new group purchasing agreement with Blood Centers of America. Cerus also reaffirmed its 2026 product revenue guidance of $224 million to $228 million and expects its third consecutive year of positive adjusted EBITDA.
CERS Earnings History & Surprises | EPS & Revenue Results | CERUS CORP (NASDAQ:CERS)
This article provides a detailed historical overview of CERUS CORP (NASDAQ: CERS) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights that CERS last reported earnings on March 2, 2026, missing both EPS and revenue estimates for that quarter. The company has a record of beating EPS estimates in 3 out of the last 4 quarters, with an average beat of 28.9%, but has missed revenue estimates in 3 out of the last 4 quarters, with an average miss of 6.2%.
Cerus 10-K: Revenue $233.8M, product growth drives results
Cerus reported total revenue of $233.8 million for the year, a 16% increase, primarily driven by higher product sales which reached $206.1 million. The company's 10-K filing also highlighted $82.9 million in combined cash and short-term investments, and ongoing progress in clinical programs and market adoption for its blood safety platforms. Growth was further supported by U.S. approvals for various systems and government contracts.
Cerus: Q4 Earnings Snapshot
Cerus Corp. (CERS) reported a net loss of $2.2 million, or 1 cent per share, in its fourth quarter, with revenue reaching $57.8 million. For the full year, the biomedical products company experienced a loss of $15.6 million, equivalent to 8 cents per share, on revenue of $206.1 million. The data for this report was generated by Automated Insights using information from Zacks Investment Research.
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were down significantly on Tuesday morning, with the Dow futures falling around 800 points. Several companies, including MongoDB, Surgery Partners, and Harrow, saw their stock prices drop sharply in pre-market trading after reporting mixed financial results or issuing lower-than-expected guidance. MongoDB beat quarterly earnings and revenue estimates but provided first-quarter adjusted EPS guidance below analyst expectations, causing its shares to dip over 27%.
Cerus Corp (NASDAQ:CERS) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss
Cerus Corporation (NASDAQ:CERS) announced mixed financial results for Q4 2025, reporting revenue of $64.6 million, which missed analyst estimates, and a net loss of $0.01 per share. Despite the quarterly miss, the company highlighted record full-year 2025 product revenue and provided 2026 guidance that was more conservative than market expectations. The stock fell over 3% in after-hours trading due to the revenue miss and wider-than-expected loss.
Cerus (Nasdaq: CERS) grows 2025 revenue 16% and reaffirms 2026 outlook
Cerus Corporation reported strong financial results for 2025, with total revenue increasing by 16% to $233.8 million and product revenue by 14% to $206.1 million. The company narrowed its net loss to $15.6 million and achieved positive non-GAAP adjusted EBITDA of $9.5 million. For 2026, Cerus reaffirmed its product revenue guidance of $224-$228 million, representing 9%-11% growth, including expected IFC revenue of $20-$22 million.
Cerus: Q4 Financial Results Overview
Cerus Corp. reported a net loss of $2.2 million, or $0.01 per share, for the fourth quarter, with revenues of $57.8 million. For the full year, the biomedical company posted a total loss of $15.6 million, or $0.08 per share, on annual revenues of $206.1 million. These financial results were generated by Automated Insights using Zacks Investment Research data.
Cerus Corp expected to post a loss of 1 cent a share - Earnings Preview
Cerus Corp (CERS) is projected to report a loss of 1 cent per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview.
Earnings Preview For Cerus
Cerus (NASDAQ: CERS) is scheduled to release its quarterly earnings report on Monday, March 2, 2026. Analysts expect an EPS of $-0.01. The report highlights Cerus's past performance, including a 21.28% share price increase after beating EPS estimates last quarter, and details financial metrics such as market capitalization, revenue growth, net margin, and debt management.
Earnings Preview For Cerus
Cerus (NASDAQ: CERS) is scheduled to release its quarterly earnings report on Monday, March 2, 2026, with analysts estimating an EPS of $-0.01. The company has a history of beating EPS estimates, leading to share price increases. Investors will be closely watching for financial guidance, noting the company's strong revenue growth and net margin, despite a lower-than-average market capitalization and ROE.
Live Cerus fireside chat set for TD Cowen health conference March 3
Cerus Corporation (Nasdaq: CERS) announced that its management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be available on the company's investor relations page, with a replay accessible for 90 days. Cerus is dedicated to blood supply safety, developing pathogen-protected blood components globally.
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after market close. The company will also host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview. Interested parties can access the webcast and presentation slides via the Investor Relations page of the Cerus website.
Cerus sets March 2 date for Q4 and full-year 2025 earnings call
Cerus Corporation (Nasdaq: CERS) announced it will release its fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET to discuss the results and provide a business overview and outlook. A replay of the webcast will be available on the Cerus website until March 23, 2026.
Cerus director Timothy L. Moore to step down after 2026 annual meeting
Cerus Corporation announced that director Timothy L. Moore will not seek re-election at the 2026 annual meeting of stockholders, with his current term expiring at that meeting. His decision was not due to any disagreements with the company. This announcement follows recent positive financial news for Cerus, including strong preliminary fourth-quarter product revenue and a new purchasing agreement.
